Nutritional Manipulation of Primate Retinas, V: Effects of Lutein, Zeaxanthin, and<i>n</i>–3 Fatty Acids on Retinal Sensitivity to Blue-Light–Induced Damage

Barker, Felix M.; Snodderly, D. Max; Johnson, Elizabeth J.; Schalch, Wolfgang; Koepcke, W.; Gerß, Joachim; Neuringer, Martha

doi:10.1167/iovs.10-5898

Cited by 168 publications

(115 citation statements)

References 58 publications

(77 reference statements)

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…They play an important role as antioxidants to prevent against oxidative stress (Bernstein et al, 2016). Due to the absorbance maximum of lutein and zeaxanthin around 460 nm, both compounds act as blue filters for UV light (Barker et al, 2011). Both pigments show weak and broad emission at 550 nm max.…”

Section: Lutein and Zeaxanthinmentioning

confidence: 99%

See 1 more Smart Citation

Fluorescence lifetime imaging ophthalmoscopy

Dysli

Wolf

Zinkernagel

2017

Acta Ophthalmologica

View full text Add to dashboard Cite

a b s t r a c tImaging techniques based on retinal autofluorescence have found broad applications in ophthalmology because they are extremely sensitive and noninvasive. Conventional fundus autofluorescence imaging measures fluorescence intensity of endogenous retinal fluorophores. It mainly derives its signal from lipofuscin at the level of the retinal pigment epithelium. Fundus autofluorescence, however, can not only be characterized by the spatial distribution of the fluorescence intensity or emission spectrum, but also by a characteristic fluorescence lifetime function. The fluorescence lifetime is the average amount of time a fluorophore remains in the excited state following excitation. Fluorescence lifetime imaging ophthalmoscopy (FLIO) is an emerging imaging modality for in vivo measurement of lifetimes of endogenous retinal fluorophores. Recent reports in this field have contributed to our understanding of the pathophysiology of various macular and retinal diseases.Within this review, the basic concept of fluorescence lifetime imaging is provided. It includes technical background information and correlation with in vitro measurements of individual retinal metabolites. In a second part, clinical applications of fluorescence lifetime imaging and fluorescence lifetime features of selected retinal diseases such as Stargardt disease, age-related macular degeneration, choroideremia, central serous chorioretinopathy, macular holes, diabetic retinopathy, and retinal artery occlusion are discussed. Potential areas of use for fluorescence lifetime imaging ophthalmoscopy will be outlined at the end of this review.

show abstract

Section: Lutein and Zeaxanthinmentioning

confidence: 99%

“…The macular pigment mainly consists of the retinal carotenoids lutein and zeaxanthin (Wustemeyer et al, 2003;Neuringer et al, 2004;Johnson et al, 2005;Leung et al, 2005;Barker et al, 2011;Lima et al, 2016). Its absorption spectrum lays between 400 and 540 nm with a peak at 460 nm.…”

Section: Fluorescence Lifetimes Of Retinal Fluorophores Ex Vivomentioning

confidence: 99%

Fluorescence lifetime imaging ophthalmoscopy

Dysli

Wolf

Zinkernagel

2017

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…2 The Age-Related Eye Disease Study (AREDS) demonstrated that daily oral supplementation with antioxidant vitamins and minerals reduced the risk of developing advanced AMD by 25% at 5 years. 4 Animal studies [5][6][7] and epidemiologic studies provide a rationale for examining the potential effects of other nutrients on the development of advanced AMD. Observational studies suggest that higher dietary intake of lutein ϩ zeaxanthin, omega-3 longchain polyunsaturated fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]), or both are associated with a decreased risk of de- veloping advanced AMD.…”

mentioning

confidence: 99%

Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration

2013

JAMA

1,066

352

View full text Add to dashboard Cite

R degeneration (AMD), the leading cause of blindness in the developed world, accounts for more than 50% of all blindness in the United States. 1 In 2004, it was estimated that 8 million individuals had intermediate AMD, defined as bilateral drusen, and approximately 2 million had advanced AMD, either neovascular AMD or geographic atrophy. 2 Although intraocular drugs that inhibit vascular endothelial growth factor are currently available for treatment of neovascular AMD, 3 no effective therapies are proven for atrophic AMD. Without more effective ways of slowing progression, the number of persons with advanced AMD is expected to double over the next 20 years, resulting in increasing socioeconomic burden. 2 The Age-Related Eye Disease Study (AREDS) demonstrated that daily oral supplementation with antioxidant vitamins and minerals reduced the risk of developing advanced AMD by 25% at 5 years. 4 Animal studies 5-7 and epidemiologic studies provide a rationale for examining the potential effects of other nutrients on the development of advanced AMD. Observational studies suggest that higher dietary intake of lutein ϩ zeaxanthin, omega-3 longchain polyunsaturated fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]), or both are associated with a decreased risk of developing advanced AMD. [8][9][10][11] Lutein and zeaxanthin are the main components of the macular pigment, DHA is a ma-*The authors/members of the Age-Related Eye Disease Study 2 (AREDS2) Writing Team are listed at the end of this article. Members of the AREDS2 Research Group are listed in the eAppendix available at http: //www.jama.com.

show abstract

“…Lutein can act as a blue light filter absorbing between 390 and 540 nm, thereby protecting the underlying photoreceptors in the macula from photochemical damage [23]. As a powerful antioxidant, lutein may also protect the macula from oxidative stress [24][25][26].…”

Section: Does Lutein Affect Age-related Macular Degeneration (Amd)?mentioning

confidence: 99%

Lutein and Factor D: Two intriguing players in the field of age-related macular degeneration

Tian

Kijlstra

Webers

et al. 2015

Archives of Biochemistry and Biophysics

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is a progressive eye disease that impairs central vision among elderly populations in Western, industrialized countries. In this review we will focus on the role of factor D (FD) and lutein in AMD. FD is a rate-limiting enzyme of the alternative complement activation pathway that may play an important role in the development of AMD. Several independent studies have shown a significant increase in the level of a number of complement factors of the alternative pathway, including factor D in the blood of AMD patients as compared to healthy individuals, which suggests a systemic involvement in the pathogenesis of AMD. FD, also called adipsin, is mainly produced by adipose tissue. Besides playing a role in the activation of the alternative pathway, FD is also known to regulate the immune system. Of interest is our preliminary finding that lutein supplementation of early AMD cases was shown to lower the level of systemic FD. If confirmed, these findings provide further support for the application of anti-factor D intervention as a new approach to control the development of this disease.

show abstract

Nutritional Manipulation of Primate Retinas, V: Effects of Lutein, Zeaxanthin, andn–3 Fatty Acids on Retinal Sensitivity to Blue-Light–Induced Damage

Abstract: After long-term xanthophyll deficiency, L or Z supplementation protected the fovea from blue light-induced damage, whereas adequate n-3 fatty acid levels reduced the damage in the parafovea.

Cited by 168 publications

References 58 publications

Fluorescence lifetime imaging ophthalmoscopy

Fluorescence lifetime imaging ophthalmoscopy

Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration

Lutein and Factor D: Two intriguing players in the field of age-related macular degeneration

Contact Info

Product

Resources

About